Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Paolo F. Caimi(Case Western Reserve University), Weiyun Z. Ai(University of California, San Francisco), Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Kirit M. Ardeshna(University College London), Mehdi Hamadani(Medical College of Wisconsin), Brian Hess(Medical University of South Carolina), Brad S. Kahl(Washington University in St. Louis), John Radford(National Institute for Health Research), Melhem Solh(Northside Hospital), Anastasios Stathis(Institute of Oncology Research), Pier Luigi Zinzani(University of Bologna), Karin Havenith, Jay Feingold, Shui He, Yajuan Qin, David Ungar, Xiaoyan Zhang, Carmelo Carlo‐Stella(Humanitas University)
The Lancet Oncology
May 11, 2021
Cited by 413

Abstract


Related Papers

No related papers found

Powered by citation graph analysis